tradingkey.logo

Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response

ReutersJun 1, 2025 2:46 PM

- Arcus Biosciences Inc RCUS.N:

  • INITIAL DATA FROM THE ARC-20 STUDY OF CASDATIFAN PLUS CABOZANTINIB SHOWED NEARLY HALF OF PATIENTS WITH METASTATIC KIDNEY CANCER HAD A CONFIRMED RESPONSE

  • ARCUS BIOSCIENCES INC - ARC-20 STUDY SHOWS 46% RESPONSE RATE IN METASTATIC KIDNEY CANCER

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI